PubMed:6222769 / 1222-1424 JSONTXT

{"project":"mondo_disease","denotations":[{"id":"T7","span":{"begin":172,"end":201},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007526"},{"id":"A8","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0020682"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"Glycan-GlyCosmos","denotations":[{"id":"T4","span":{"begin":152,"end":163},"obj":"Glycan"},{"id":"T16","span":{"begin":4,"end":19},"obj":"Glycan"}],"attributes":[{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G43702JT"},{"id":"A17","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT"},{"id":"A16","pred":"image","subj":"T16","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G17927IW"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos-GlycoEpitope","denotations":[{"id":"T10","span":{"begin":4,"end":19},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T11","span":{"begin":152,"end":163},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A10","pred":"glycoepitope_id","subj":"T10","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A11","pred":"glycoepitope_id","subj":"T11","obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-MONDO","denotations":[{"id":"T7","span":{"begin":172,"end":201},"obj":"Disease"}],"attributes":[{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0007526"},{"id":"A8","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0020682"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-CL","denotations":[{"id":"T1","span":{"begin":100,"end":108},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0000233"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T8","span":{"begin":100,"end":108},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CL_0000233"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T8","span":{"begin":0,"end":202},"obj":"Sentence"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T4","span":{"begin":152,"end":163},"obj":"Glycan"},{"id":"T16","span":{"begin":4,"end":19},"obj":"Glycan"}],"attributes":[{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G43702JT"},{"id":"A17","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G43702JT"},{"id":"A16","pred":"image","subj":"T16","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G17927IW"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"GlyCosmos15-GlycoEpitope","denotations":[{"id":"T10","span":{"begin":4,"end":19},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"},{"id":"T11","span":{"begin":152,"end":163},"obj":"http://purl.jp/bio/12/glyco/glycan#Glycan_epitope"}],"attributes":[{"id":"A10","pred":"glycoepitope_id","subj":"T10","obj":"http://www.glycoepitope.jp/epitopes/EP0086"},{"id":"A11","pred":"glycoepitope_id","subj":"T11","obj":"http://www.glycoepitope.jp/epitopes/EP0081"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T8","span":{"begin":100,"end":108},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CL_0000233"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}

{"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":100,"end":108},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0000233"}],"text":"The heparan sulfate proteoglycan preparations exhibited significantly more potent anticoagulant and platelet aggregation inhibitory activities than the chondroitin sulfate-dermatan sulfate proteoglycan."}